zomiradomide   Click here for help

GtoPdb Ligand ID: 11904

Synonyms: compound A [WO2022027058A1]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This compound in an IRAK4 degrader (PROTAC) that is claimed in Kymera Therapeutics' patent WO2022027058A1 [1]. It is intended as a therapeutic for B-cell lymphomas that express oncogenic mutations in MYD88, e.g. the protein variant MYD88L265P. The cereblon binding portion of the molecule is based on the structure of the immunomodulatory imide drug (IMiD) lenalidomide. Compound A simultaneously promotes the degradation of IRAK4 and the zinc-finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), and this mechanism synergistically targets key pro-survival pathways in B-cell lymphomas (MYD88-NFκB and IRF4-Type 1 interferon) to enhance anti-tumour activity. The chemical structure for Compound A matches that for the INN zomiradomide in proposed INN list 130 (Feb. 2024), and we suspect that this is their pipeline lead candidate KT-413.

We have curated structural and other information for a different clinical stage Kymera IRAK4/IMDi PROTAC known as KT-474 that is being evaluated for efficacy in autoinflammatory diseases.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 13
Hydrogen bond donors 4
Rotatable bonds 13
Topological polar surface area 202.17
Molecular weight 871.33
XLogP 4.66
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C1CCC(C(=O)N1)N1C(=O)c2c(C1=O)cccc2NCCC1CC2(C1)CN(C2)C[C@@H]1CC[C@H](CC1)c1sc2c(n1)cc(c(c2)NC(=O)c1cccc(n1)C(F)(F)F)C(O)(C)C
Isomeric SMILES CC(C)(O)c1cc2c(sc(n2)[C@H]2CC[C@H](CN3CC4(CC(CCNc5c6C(=O)N(C7CCC(=O)NC7=O)C(=O)c6ccc5)C4)C3)CC2)cc1NC(=O)c1cccc(n1)C(F)(F)F
InChI InChI=1S/C45H48F3N7O6S/c1-43(2,61)28-17-32-34(18-31(28)51-38(57)30-7-4-8-35(50-30)45(46,47)48)62-40(52-32)26-11-9-24(10-12-26)21-54-22-44(23-54)19-25(20-44)15-16-49-29-6-3-5-27-37(29)42(60)55(41(27)59)33-13-14-36(56)53-39(33)58/h3-8,17-18,24-26,33,49,61H,9-16,19-23H2,1-2H3,(H,51,57)(H,53,56,58)/t24-,26-,33?
InChI Key WDRJGMSUTPVXDH-KBOGUJPVSA-N
Classification Click here for help
Compound class Synthetic organic
Ligand families/groups PROTACs, molecular glues and other degraders
IUPAC Name Click here for help
N-[2-[4-[[6-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethyl]-2-azaspiro[3.3]heptan-2-yl]methyl]cyclohexyl]-5-(2-hydroxypropan-2-yl)-1,3-benzothiazol-6-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
International Nonproprietary Names Click here for help
INN number INN
12914 zomiradomide
Synonyms Click here for help
compound A [WO2022027058A1]
Database Links Click here for help
CAS Registry No. 2655656-99-6 (source: WHO INN record)
GtoPdb PubChem SID 461663459
PubChem CID 156506667
Search Google for chemical match using the InChIKey WDRJGMSUTPVXDH-KBOGUJPVSA-N
Search Google for chemicals with the same backbone WDRJGMSUTPVXDH
Search PubMed clinical trials zomiradomide
Search PubMed titles zomiradomide
Search PubMed titles/abstracts zomiradomide
UniChem Compound Search for chemical match using the InChIKey WDRJGMSUTPVXDH-KBOGUJPVSA-N
UniChem Connectivity Search for chemical match using the InChIKey WDRJGMSUTPVXDH-KBOGUJPVSA-N